Work

Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors

Year: 2020

Type: article

Study design: Clinical Trial

Source: European Journal of Cancer

DOI: 10.1016/s0959-8049(20)31094-7

Authors: F. Janku, R. Abdul-Karim, A. Azad, J. Bendell, H. Gan, S. Sen, T. Tan, J. Wang, N. Marina, L. Baker, L. Ma, J. Mooney, D. Luo, J. Leveque, M. Milla, T. Meniawy

Institutions: The University of Texas MD Anderson Cancer Center, Texas Oncology, Peter MacCallum Cancer Centre, Sarah Cannon, Tennessee Oncology, Austin Health, Olivia Newton-John Cancer Research Institute, HealthONE, National Cancer Centre Singapore, Linear Clinical Research

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3097133636

FWCI: 0.181

Cites:

Cited by: 2

Related to: 10